Most of the mammalian genome is transcribed [1] [2] [3] . This generates a vast repertoire of transcripts that includes protein-coding messenger RNAs, long non-coding RNAs (lncRNAs) and repetitive sequences, such as SINEs (short interspersed nuclear elements). A large percentage of ncRNAs are nuclear-enriched with unknown function 4 . Antisense lncRNAs may form sense-antisense pairs by pairing with a protein-coding gene on the opposite strand to regulate epigenetic silencing, transcription and mRNA stability [5] [6] [7] [8] [9] [10] . Here we identify a nuclear-enriched lncRNA antisense to mouse ubiquitin carboxyterminal hydrolase L1 (Uchl1), a gene involved in brain function and neurodegenerative diseases 11 . Antisense Uchl1 increases UCHL1 protein synthesis at a post-transcriptional level, hereby identifying a new functional class of lncRNAs. Antisense Uchl1 activity depends on the presence of a 59 overlapping sequence and an embedded inverted SINEB2 element. These features are shared by other natural antisense transcripts and can confer regulatory activity to an artificial antisense to green fluorescent protein. Antisense Uchl1 function is under the control of stress signalling pathways, as mTORC1 inhibition by rapamycin causes an increase in UCHL1 protein that is associated to the shuttling of antisense Uchl1 RNA from the nucleus to the cytoplasm. Antisense Uchl1 RNA is then required for the association of the overlapping sense protein-coding mRNA to active polysomes for translation. These data reveal another layer of gene expression control at the post-transcriptional level.
To discover non-coding antisense transcripts of sense-antisense (S-AS) pairs expressed in the brain, the mouse syntenic loci of genes involved in neurodegenerative diseases were identified computationally and examined in the Ensembl browser (http://www.ensembl.org). The FANTOM2 clone 6430596G22 was classified as a spliced antisense lncRNA of the Uchl1 gene 11 ; we refer to this as antisense Uchl1. UCHL1 is a neuron-restricted protein that acts as a deubiquitinating enzyme, ubiquitin ligase or monoubiquitin stabilizer 12 . An in-frame deletion in the Uchl1 gene, as in gracile axonal dystrophy mice, leads to ataxia and axonal degeneration. Although an association of UCHL1 gene mutations to familial Parkinson's disease has not been confirmed in independent families, oxidative inactivation of UCHL1 protein has been reported in Parkinson's disease and Alzheimer's disease brains [13] [14] [15] . Antisense Uchl1 is a 59 head-to-head transcript that initiates within the second intron of Uchl1 and overlaps the first 73 nucleotides of the sense mRNA including the AUG codon. By 59 rapid amplification of cDNA ends (RACE), the transcriptional start site (TSS) of antisense Uchl1 was mapped to the second intron of Uchl1 (Fig. 1a) . The nonoverlapping part of the transcript contains two embedded repetitive sequences, SINEB1 of the F1 subclass (Alu) and SINEB2 of the B3 subclass, identified by Repeatmasker [16] [17] [18] . The FANTOM2 clone spans a genomic region of 70 kilobases (kb) (Fig. 1a) and its genomic organization is conserved in mammals ( Supplementary Fig. 1a ).
Sense and antisense Uchl1 expression in mouse and human tissues was similar (Fig. 1b and Supplementary Fig. 1b ). In the mouse, antisense Uchl1 RNA was highly expressed in the ventral midbrain (Fig. 1b) and in the MN9D dopaminergic cell line (data not shown). Mature Uchl1 mRNA was observed mainly in the cytoplasm of dopaminergic neurons, whereas antisense Uchl1 was enriched in the nucleus ( Fig. 1c and Supplementary Fig. 2 ). Antisense Uchl1 expression was confirmed by qRT-PCR from dopaminergic neurons purified with laser capture microdissection (LCM, Supplementary Fig. 3 ). Transient expression of antisense Uchl1 in MN9D cells caused no significant change in endogenous Uchl1 mRNA expression. Notably, a strong and reproducible upregulation of UCHL1 protein was detected within 24 h (Fig. 2a) . When increasing amounts of antisense Uchl1 were co-transfected with murine Uchl1 into HEK cells, which do not express either transcript, dose-dependent UCHL1 protein upregulation was recorded in the absence of any significant change in the quantity of exogenous Uchl1 mRNA (Fig. 2b) . These data indicate that antisense Uchl1 regulates UCHL1 expression at a post-transcriptional level.
Antisense Uchl1 deletion constructs lacking the 59 first exon (antisense Uchl1(D59)) or the last three exons (antisense Uchl1(D39)) failed to induce UCHL1 protein in MN9D and HEK cells, suggesting that both 59 and 39 components are important to antisense Uchl1 function ( Fig. 2c and Supplementary Fig. 4a ). Targeted deletion of the region containing the embedded SINEB2 and Alu repetitive sequences (DAS) was also able to prevent UCHL1 protein induction. Deletion of each repetitive element separately revealed that SINEB2 is the functional unit required by antisense Uchl1 for increasing UCHL1 protein synthesis (Fig. 2d) . In all cases no change in Uchl1 mRNA level was detected ( Supplementary Fig. 4b ). A mutant with a flipped SINEB2 sequence was unable to increase UCHL1 protein levels, thus proving the orientationdependent activity of the SINEB2 domain embedded within antisense Uchl1 (Fig. 2d) . Importantly, an artificial construct containing the 73-nucleotide overlapping sequence immediately close to the repetitive elements in antisense Uchl1(D59) increased UCHL1 levels as much as the full-length clone ( Fig. 2e and Supplementary Fig. 4c ).
We then considered whether other SINEB2-containing lncRNAs may post-transcriptionally regulate the expression of their proteincoding partner, on the basis of similar structural elements. The FANTOM3 collection of non-coding cDNAs was bioinformatically screened for natural antisense transcripts that contain SINEB2 elements of the B3 subclass in the correct orientation and 59 head-to-head overlapping to a protein-coding gene. This identified 31 S-AS pairs similar to the Uchl1/antisense Uchl1 structure ( Supplementary Fig. 5 ). By sequence alignment, we chose antisense Uxt (4833404H03), antisense of ubiquitously expressed transcript (Uxt), as the one with the most similar SINEB2 elements (Fig. 3a) . Transfection of antisense Uxt in MN9D cells elicited an increase of UXT protein level with no change in Uxt mRNA (Fig. 3b) , indicating that antisense Uxt was similarly able to increase protein levels post-transcriptionally.
These data indicate a model whereby lncRNAs regulate protein synthesis through the combined activities of two domains. The 59 antisense AS Uchl1 - 
Uchl1

AS Uchl1
AS Uchl1 (ΔΔCt) ×1,000 LETTER RESEARCH region provides specificity for the sense target gene whereas the repetitive element confers the protein synthesis activation domain. The model predicts that by swapping the overlapping sequence one may increase the amount of proteins encoded by the mRNAs of choice acting at the post-transcriptional level. We thus synthesized a 72-nucleotide-long artificial sequence antisense to the AUG-containing region as transcribed from pEGFP, and inserted it into antisense Uchl1(D59) to generate antisense GFP (Fig. 3c) . Co-transfection of antisense GFP with pEGFP strongly increased GFP protein but not mRNA levels in HEK cells (Fig. 3d) . When we pulsed cells with methionine for an hour and immunoprecipitated GFP, antisense GFP induced an increase in radioactively labelled, neo-synthesized GFP, without affecting mRNA levels ( Supplementary Fig. 6 ).
To understand how the antisense Uchl1 transcript operates and the physiological conditions in which it might act, we assayed several stimuli and/or drugs for their ability to modulate UCHL1 protein expression. Inhibition of mTORC1 signalling favoured an increase in UCHL1 levels in a range from 1.5-to 2.5-fold (Fig. 4a) . This effect was evident with as low as 20 nM rapamycin ( Supplementary Fig. 7 ) and was concomitant with dephosphorylation of mTOR targets p70S6K and 4E-BP1. Furthermore, the effect was not due to a stabilization of the protein, as co-application of cycloheximide decreased UCHL1 protein levels ( Supplementary Fig. 8a ). These data are surprising because rapamycin impairs formation of the CAP-dependent complex and hence translation of highly structured mRNAs 19 . However, in agreement with previous reports, in our experimental settings mTORC1 inhibition only slightly impairs the global rate of translation ( Supplementary Fig. 8b ). Under these conditions, it has been proposed that rapamycin may affect competition among different mRNAs 20 . If so, we proposed that inhibition of the CAP complex formation favours the translation of Uchl1 mRNA with a mechanism that requires antisense Uchl1.
To test this model, we used two complementary approaches to establish a loss-of-function phenotype. First, we downregulated antisense Uchl1 levels with short hairpin RNA (shRNA) targeting its promoter region. MN9D cells constitutively expressing shRNA for antisense Uchl1 did not show any changes in UCHL1 protein levels upon rapamycin treatment, whereas scramble control cells showed UCHL1 upregulation as in the parental line (Fig. 4b) . Dephosphorylation of p70S6K and 4E-BP1 proved that rapamycin inhibited mTOR activity as expected. We then exploited the dominant-negative property of an antisense Uchl1 mutant lacking the SINEB2 repeat element. Overexpression of antisense Uchl1(DSINEB2) inhibited the ability of full-length antisense Uchl1 to increase protein levels ( Supplementary Fig. 9 ). Upon rapamycin treatment, cells stably expressing antisense Uchl1(DSINEB2) did not show any UCHL1 protein induction despite dephosphorylation of mTOR targets (Fig. 4c) . These complementary experiments prove that functional antisense expression is required for UCHL1 protein increase elicited by rapamycin.
Because antisense Uchl1 transcript is enriched in the nucleus of dopaminergic neurons, we measured antisense Uchl1 and Uchl1 RNA content in the nucleus and cytoplasm of MN9D cells upon rapamycin treatment. As shown in Fig. 4d , rapamycin substantially increased antisense Uchl1 concentration in the cytoplasmic fraction. This effect was confirmed by a concomitant decrease in its nuclear steady-state levels, and by the absence of any de novo transcription. The total content of primary and spliced transcripts remained constant (data not shown). Uchl1 mRNA showed no change in subcellular distribution, de novo transcription or total cellular content. These data demonstrate that antisense Uchl1 localization can be regulated by the mTOR pathway, and its cytoplasmic level correlates with the expression of UCHL1 protein.
We therefore monitored the association of Uchl1 mRNA with polysomes to assess the role of translation in antisense Uchl1-mediated UCHL1 protein induction. Fractionated MN9D cell extracts were used to measure the recruitment of Uchl1 mRNA on polysomes by qRT-PCR and northern blotting ( Fig. 4e and Supplementary Fig. 10 ). In basal conditions, Uchl1 mRNA was associated with translating ribosomes. Rapamycin treatment induced a shift of Uchl1 mRNA to heavier polysomes, consistent with an enhanced rate of translation initiation; this increase of Uchl1 mRNA association to heavier polysomes did not occur in cells overexpressing the dominant-negative form of antisense Uchl1 (Supplementary Fig. 11 ).
Antisense Uchl1 is the representative member of a new functional class of lncRNAs that are part of S-AS pairs in the mammalian genome that require overlap at the 59 end and the action of a SINEB2 repeat. This new function for SINEB2 sequences in the cytoplasm adds to their 
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well-established role in the nucleus as inhibitors of RNA polymerase II 16 . Stress-dependent nucleocytoplasmic shuttling of lncRNAs may be a common strategy to regulate translation, as CTN-RNA, another nuclear-retained lncRNA, was found to have a cryptic protein-coding sequence at its 39 end when in the cytoplasm 21 . It is intriguing that this nuclear lncRNA-mediated mechanism for post-transcriptional control of gene expression is active when CAPdependent translation is inhibited by rapamycin. This drug blocks mTORC1 kinase, which activates the eIF4F complex 19, 22 . However, some mRNAs escape mTORC1 inhibition by being able to be recruited to ribosomes in an eIF4F-independent manner for presenting complex mRNA loops that function as internal ribosomal entry sites (IRES) 23 . Indeed, IRES-mediated translation is prominent in conditions of stress or growth factor inhibition and its alteration affects processes such as tumorigenesis 22, 24 . In genetic and neurochemical models of Parkinson's disease, mTORC1 inhibition protects dopaminergic neurons from apoptosis 25, 26 . Antisense lncRNA-mediated translation may be another mechanism to maintain synthesis of pro-survival proteins, such as UCHL1, that are involved in rapamycin neuroprotective function and more generally in cellular response to stress. This mechanism may represent the outcome of an evolutionary pressure on the genomic organization of anti-stress elements to favour gene-specific regulation of translation when CAPdependent initiation is reduced. Finally, natural and synthetic antisense transcripts with embedded repetitive elements may represent molecular tools to increase translation of selected mRNAs, defining a potential new class of RNA therapeutics.
METHODS SUMMARY
59 RACE for antisense Uchl1 was performed with Gene Racer (Invitrogen). Double-fluorescence in situ hybridization of biotin-and digoxigenin-labelled probes was detected using fluorochrome-conjugated reagents. Images were captured with Confocal Laser Microscopy (LEICA). Expression of antisense Uchl1 was performed on neuronal cells lines and dopaminergic neurons purified with LCM from TH-GFP mice. Cell lines were cultured under standard conditions. shRNA targeting the promoter of antisense Uchl1 was cloned in pSUPERIOR.Neo.GFP vector (Oligo Engine). Polysomes were prepared by sucrose gradient and associated Uchl1 mRNA was measured by qRT-PCR and northern blotting.
Full Methods and any associated references are available in the online version of the paper.
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LETTER RESEARCH METHODS
Oligonucleotides. The complete list of oligonucleotides used for cloning and for quantitative real-time PCR experiments is included in Supplementary Information  (Supplementary Fig. 12 ). Plasmids. Full-length DNA sequence of antisense Uchl1 was amplified via fusion PCR starting from RACE fragment and FANTOM clone 6430596G22 (GenBank AK078321.1) with forward mouse antisense Uchl1 FL and reverse mouse antisense Uchl1 FL primers.
Mouse Uchl1 mRNA was subcloned from FANTOM clone 2900059O22 (GenBank AK013729.1) in the unique PmeI site of pcDNA3.1.
cDNA sequence of human antisense UCHL1 was amplified from a sample of human brain total RNA (Clontech, 636530) with the primers human 59F and human 39R.
Oligonucleotides that target the sequence 214/13 around the TSS of antisense Uchl1 were annealed and cloned into pSUPERIOR.Neo.GFP vector (OligoEngine) in the BglII/XhoI site. Scrambled sequence was also cloned and used as control.
The antisense Uchl1 59 deletion mutant (D59) was generated by PCR using the oligonucleotides forward mouse antisense Uchl1(D59) and reverse mouse antisense Uchl1 FL. PCR fragment was cloned in the unique EcoRI site in pcDNA3.1.
The antisense Uchl1 39 deletion mutant (D39) was generated by PCR using the forward mouse antisense Uchl1 FL and reverse mouse antisense Uchl1(D39) primers and cloned in the unique EcoRI site in pcDNA3.1.
The antisense Uchl1(DAS) (DAlu 1 SINEB2) mutant was obtained by subsequent cloning of PCR fragment I (NheI-EcoRI site) and PCR fragment II (EcoRI-HindIII site) into pcDNA3.1. Primers forward mouse antisense Uchl1 FL Nhe and reverse pre-SINE B2 EcoRI were used to generate fragment I; primers forward post-ALU EcoRI and reverse mouse antisense FL HindIII were used for PCR fragment II.
The antisense Uchl1(DA) (DAlu, 1000-1045) mutant was generated with a similar strategy to antisense Uchl1(DAS). Forward mouse antisense Uchl1 FL NheI and reverse pre-ALU EcoRI were used for PCR fragment I; forward post-ALU and reverse mouse antisense FL HindIII for PCR fragment II.
The antisense Uchl1(DS) (DSINEB2, 764-934) mutant was obtained with a similar strategy to antisense Uchl1(DAS). Oligonucleotides forward mouse AS Uchl1 FL NheI and reverse pre-SINE B2 EcoRI for fragment I; forward post-SINE B2 EcoRI and reverse mouse AS FL HindIII for fragment II.
For antisense Uchl1(ASf) (Alu 1 SINEB2 flipped), PCR fragment obtained with the primers forward SINEB2 inside and reverse Alu flip was cloned in the unique EcoRI site of antisense Uchl1(DAS).
For antisense Uchl1(Sf) (SINEB2 flipped), PCR fragment obtained with forward SINE B2 inside and reverse SINE flip oligonucleotides was cloned in the unique EcoRI site of antisense Uchl1 DSINEB2.
For antisense Uchl1(73 bp), the method of 'annealing and primer extension' of two 39-end overlapping oligonucleotides was used to generate the 73-bp antisense Uchl1 overlap region. Annealed fragment was obtained with antisense Uchl1 73 bp forward and antisense Uchl1 73 bp reverse. Fragment was digested with XhoI and EcoRV and ligated into antisense Uchl1 D59 plasmid.
The antisense SCR 73-bp mutant was obtained with a similar strategy as antisense Uchl1(73 bp). The annealing extension was performed with oligonucleotides with scramble (SCR) sequence (antisense SCR forward and antisense SCR reverse).
Full-length mouse antisense Uxt was amplified by PCR starting from FANTOM clone 4833404H03 (GenBank AK029359.1) with specific primers (forward mouse antisense Uxt and reverse mouse antisense Uxt). PCR fragment was subcloned into pcDNA3.1 using XbaI and HindIII restriction enzymes.
The antisense GFP plasmid was generated with a similar strategy as antisense Uchl1(73 bp). Seventy-two base pairs corresponding to nucleotide 240/132 with respect to the ATG of GFP sequence in pEGFP-C2 vector (Clontech) were chosen as target sequence for artificial antisense DNA generation. For annealing, the GFP antisense forward and GFP antisense reverse primers were used. Cells. MN9D cells were obtained from M. J. Zigmond. Cells were seeded in 100-mm dishes in Dulbecco's modified Eagle's (DMEM) medium containing 10% fetal bovine serum (Invitrogen) supplemented with penicillin (50 units ml
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) and streptomycin (50 units ml Animal handling. All animal experiments were performed in accordance with European guidelines for animal care and following SISSA Ethical Committee permissions. Mice were housed and bred in SISSA/CBM non-SPF animal facility, with 12 h dark/light cycles and controlled temperature and humidity. Mice had ad libitum access to food and water. C57BL/6 male mice (n 5 5), 8-10 weeks old, were used for in situ hybridization experiments. Laser capture microdissection (LCM) of dopaminergic neurons was performed on 8-10-week-old male TH-GFP/21-31 mice (n 5 3). Intra-cardiac perfusions were done under total anaesthesia. RACE and multiplex RT-PCR. The 59 UTR of antisense Uchl1 was amplified by RACE PCR (GeneRacer, Invitrogen) by MN9D total RNA and cloned into pGEM-T Easy vector (Promega). qRT-PCR. Total RNA was extracted from cells and mouse tissue samples (adrenal gland, cerebellum, cortex, olfactory bulb, striatum, ventral midbrain, heart, colon, kidney, lung, lymph node, ovary, prostate, spleen, testis, uterus) using Trizol reagent (Invitrogen) according to the manufacturer's instruction. An RNA panel of 20 different normal human tissues (pools consist of at least three tissue donors with full documentation on age, sex, race, cause of death) was obtained from Ambion (AM6000). All RNA samples were subjected to DNase I treatment (Ambion). A total of 1 mg of RNA was subjected to retrotranscription using iScript cDNA synthesis kit (BioRad) and Real Time qRT-PCR was carried out using SYBR green fluorescence dye (23 iQ5 SYBR Green supermix, BioRad). TATA-binding protein (TBP) and RNA polymerase II (RPII) were used as housekeeping genes to normalize different mouse and human tissues as tested by the GeNorm program, version 3.5 (http://medgen.ugent.be/genorm/) 27 . GAPDH and b-actin were used as normalizing controls in all the other qRT-PCR experiments. The amplified transcripts were quantified using the comparative Ct method and the differences in gene expression were presented as normalized fold expression (DDCt). All of the experiments were performed in duplicate. A heat map graphical representation of rescaled normalized fold expression (DDCt/DDCt max ) was obtained by using Matrix2png (http://www.bioinformatics.ubc.ca/matrix2png/). A list of oligonucleotides used for qRT-PCR experiments is in Supplementary  Fig. 12 . LCM technology. For LCM, regions of midbrain from TH-GFP/21-31 mice were dissected and incubated in 13 Zincfix solution for 6 h. They were then cryoprotected in 30% sucrose solution at 4 uC overnight, embedded in Neg-50 section medium, snap-frozen and left to equilibrate in a cryostat chamber at 221 uC for 1 h before sectioning, as described earlier 28 . Cryostat 14 mm midbrain coronal sections were thaw-mounted on Superfrost plus glass slides (Mezzle-Glasser) and dopaminergic GFP 1 cells were gathered via LCM and collected in microfuge (PALM adhesive caps). RNA was immediately extracted using the Absolutely RNA Nanoprep kit (Stratagene), eluted in RNase/DNase free water (Ambion) and retro-transcribed. Two-colour in situ hybridization. After perfusion with 4% formaldehyde, mouse brain was cryoprotected overnight in 30% sucrose. In situ hybridization was performed on cryostat slices (16 mm). Sense and antisense probes were generated by in vitro transcription from the cDNA encoding the distal 600 bp of mouse Uchl1 cDNA and the last 1,000 bp of mouse antisense Uchl1. The probes for Uchl1 and antisense Uchl1 were labelled with digoxigenin (DIG labelling, Roche) and biotin (BIO-labelling mix, Roche), respectively. Incorporation of biotin and digoxigenin was checked via a northern blot assay. In situ hybridization was performed as described previously 29 . Slices were pre-treated with 3% hydrogen peroxide for 30 min. Hybridization was performed with probes at a concentration of 1 mg ml 21 (Uchl1) and 3 mg ml 21 (antisense Uchl1) at 60 uC for 16 h. For biotinylated RNA detection, streptavidin-HRP (Amersham Bioscience) was used (1:250) for 2 h in TNB buffer (Tris HCl pH 7.5 100 mM, NaCl 150 mM, 0.5% blocking reagent), and signals were visualized using the TSA Cy3 system (Perkin Elmer) after washing in TNT buffer (Tris HCl pH 7.5 100 mM, NaCl 150 mM, 0.05% Tween-20). In situ hybridization on DIG-labelled probe was performed with monoclonal anti-DIG antibody after TSA reaction. To combine RNA in situ hybridization with immunofluorescence, slices were incubated with anti-tyrosine hydroxylase (TH) antibody 1:1,000 (Chemicon). Signals were then detected with fluorescent dye-conjugated secondary antibody goat anti-rabbit 405 and goat anti-mouse 488. Sections were then washed, mounted with Vectashield (Vector lab) mounting medium and observed with a confocal microscope (Leica). Western blot. Cells were lysed in SDS sample buffer 23. Proteins were separated in 15% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. Immunoblotting was performed with the following primary antibodies: anti-UCHL1 (3524 Cell Signaling), anti-UXT (11047-1-AP Proteintech Group), antip53 (1C12) monoclonal antibody (2524, Cell Signaling) and anti-b-actin (A5441, Sigma). For the mTOR pathway: anti-phospho-p70 S6 kinase (Thr 389) (9234), anti-phospho-4E-BP1 (Ser 65) (9451), anti-p70 S6 kinase (9202), anti-4E-BP1 (9452), anti-phospho-Akt (Ser 473) (3787) were all purchased from Cell Signaling. Signals were revealed after incubation with recommended secondary antibodies RESEARCH LETTER
